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RESUMO – Lúpus eritematoso cutâneo engloba um vasto leque de manifestações dermatológicas, que podem ou não acompa-
nhar-se de acometimento sistémico. As lesões cutâneas específicas – definidas histologicamente pela presença de dermatite de 
interface – são ainda dividas em subtipos, concretamente lúpus agudo, subagudo ou crónico. O subtipo crónico inclui ainda o 
lúpus discóide, bem como variantes mais raras, como o lúpus profundo. As manifestações cutâneas não específicas, nomeada-
mente o livedo reticular ou purpura, são mais frequentes nos doentes com acometimento sistémico. A abordagem diagnóstica 
implica a correcta subclassificação do subtipo, através duma combinação de exame físico, estudo laboratorial, análise histoló-
gica e ocasionalmente imunofluorescência directa, sendo imperativo a exclusão de atingimento sistémico. 
Do ponto de vista terapêutico, os corticosteróides tópicos e antimaláricos permanecem como a base da terapêutica; no entanto, 
imunossupressores, análogos da talidomida e anticorpos monoclonais são terapias sistémicas disponíveis para o tratamento da 
doença recalcitrante. A educação do doente acerca de medidas de fotoproteção e evicção de factores despoletantes é fulcral. 
PALAVRAS-CHAVE – Lúpus Eritematoso Cutâneo/complicações; Lúpus Eritematoso Cutâneo/diagnóstico; Lúpus Eritematoso 
Cutâneo/tratamento.
Lupus Erythematosus: Cutaneous Manifestations and 
Treatment 
ABSTRACT – Cutaneous lupus erythematosus (CLE) includes a broad range of dermatologic manifestations, which may or may not 
be associated with systemic manifestations. Specific CLE - defined by the presence of an interface dermatitis on histopathological 
evaluation -  is divided into several sub-types, namely acute CLE (ACLE), subacute CLE (SCLE) and chronic CLE (CCLE). CCLE in-
cludes discoid lupus erythematosus (DLE), as well as other rarer forms such as LE profundus (LEP). Nonspecific skin findings, such 
as livedo reticularis or purpura are more frequently seen in patients with systemic disease. Diagnosis requires classification of the 
subtype, through a combination of physical examination, laboratory studies, histology and sometimes direct immunofluorescence, 
at the same time ensuring to exclude systemic disease. 
Regarding the treatment of CLE, antimalarials and topical steroids continue to be the standard of care; however, immunosuppres-
sants, thalidomide analogs and monoclonal antibodies are possible systemic therapies for recalcitrant disease. Patient education 
on proper sun protection and avoidance of triggers is crucial. This paper reviews the clinical manifestations of CLE, as well as the 
treatment. 
KEY WORDS – Lupus Erythematosus, Cutaneous/complications; Lupus Erythematosus, Cutaneous/diagnosis; Lupus Erythemato-
sus, Cutaneous/therapy.
1. INTRODUCTION
Lupus erythematosus (LE) is a complex chronic autoimmu-
ne disease. LE presents with a wide spectrum of clinical and 
immunological features and is characterized by pathogenic 
autoantibodies and immune complexes, attributed to loss 
of immune tolerance. Systemic lupus erythematosus (SLE) 
may encompass severe systemic organ involvement (kidney, 
blood, central nervous system, heart, etc.) in which the skin 
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is also a frequently involved. However, in certain cases, LE 
affects only the skin. 
Cutaneous lupus erythematosus (CLE) includes a broad 
range of dermatologic manifestations, which can be a source 
of significant morbidity. Cutaneous manifestations can be the 
single manifestation of LE, but cutaneous involvement is very 
common in patients with systemic manifestations. In up to 25% 
of cases skin lesions are the presenting sign of SLE and they 
are present in approximately 80% of patients during the cour-
se of the disease.1 In fact, after articular involvement, the skin 
represents the second most frequently affected organ in SLE. 2 
2. EPIDEMIOLOGY
Lupus erythematosus is a common disease and its inciden-
ce in the general population is variable, depending on para-
meters of the studied population, such as ethnicity, age, sex, 
race and national origin. Most studies evaluated the incidence 
of SLE, and epidemiological data of the different subtypes of 
CLE have been more rarely investigated, but CLE appears to 
be two to three times more frequent than SLE.3 
Two population-based studies reported an incidence of 4 
new cases of CLE per 100 000 inhabitants per year, in Sweden 
and USA4,5 with an estimated prevalence around 70 cases per 
100 000 persons.6 Highlighting the importance of skin disea-
se in LE, there appear to be approximately as many patients 
who have cutaneous LE without concurrent SLE as there are 
patients who have SLE.4,5 The mean age at diagnosis with CLE 
is around 54 years.5
As for risk factors, the strongest factor affecting risk for 
lupus is gender, with a clear female predominance. Regar-
ding only cutaneous involvement, female patients with CLE 
still outnumber males, with female-to-male ratio estimated to 
be 3:1.5 
Another major risk factor is ethnicity. The prevalence of SLE 
is fourfold higher in African-American women as compared 
to Caucasian American women (4 in 1000 vs 1 in 1000).7 
Moreover, African-Americans tend to develop disease at an 
earlier age, and are prone to more severe forms, with a hi-
gher mortality rate. SLE is also more common in Asians versus 
Caucasians.8
The risk of developing SLE differs according to the type 
of skin involvement: it is substantially higher in patients with 
ACLE than in patients with localized DLE. After an initial 
diagnosis of CLE, the risk of developing SLE has been esti-
mated to be between 5% and 18% within three to five years 
of follow-up.4,5 
3. CUTANEOUS LESIONS IN LUPUS ERYTHEMATOSUS 
Skin lesions are classically separated, according to Gi-
lliam and Sontheimer’s classification, into specific and non-
-specific skin manifestations, depending on the presence 
of an interface dermatitis on histopathological evaluation, 
defined by the presence of vacuolization and necrosis of 
basal keratinocytes and a lymphocytic infiltrate at the der-
mo-epidermal junction.9,10 These specific cutaneous lesions, 
included under the designation of cutaneous LE (CLE), are 
subdivided into acute, subacute and chronic subtypes based 
on clinical, histological, and serological features plus avera-
ge duration of skin lesions: acute cutaneous LE (ACLE), suba-
cute CLE (SCLE), and chronic cutaneous LE (CCLE). Chronic 
CLE includes discoid LE (DLE) and the less common variants 
of LE profundus/panniculitis and chilblain LE.11 LE tumidus, 
initially included within the chronic subtype, is considered a 
separate form of cutaneous LE.12,13 In a large study of more 
than thousand patients in Sweden, DLE was the most com-
mon subset (80%), followed by SCLE (15%), and less than 5% 
are other more rare types of CLE.5
The LE-nonspecific manifestations are more frequently 
seen in patients with systemic disease and may also occur in 
other autoimmune diseases; they include vascular changes, 
exanthema, alopecia and mucous membrane lesions.14 
3.1. Acute Cutaneous Lupus Erythematosus 
ACLE typically presents in the third decade of life, and is 
often associated with active SLE.15,16 Acute cutaneous lesions 
are usually localized, but can be generalized. They tend to 
be sun-induced, transient and resolve without scarring, al-
though dyspigmentation can occur, especially in patients with 
darker skin. 
The localized form of acute CLE, classically described as 
“butterfly” or “malar” rash, is present in about half of SLE 
patients at the time of diagnosis, and can precede the onset 
of systemic involvement by weeks or months. The “butter-
fly” rash is characterized by bilateral pink-red erythematous 
lesions in the malar areas extending over the nasal bridge, 
typically sparing the nasolabial folds and the periorbital re-
gions11 (Fig.1a). Lesions vary from macular erythema (the 
most frequent) to intense edematous confluent papules and 
plaques, but scaling, erosions and crusting may also be pre-
sent, and differential diagnosis with rosacea, seborrheic der-
matitis or other facial eruptions have to be considered.
Palms and soles may also be affected and lesions on the 
dorsum of the hands occur between the metacarpophalan-
geal and interphalangeal joints typically sparing the knuck-
les, while the opposite occurs in dermatomyositis1 (Fig. 1b).
Erythema and hemorrhaging patches on the hard palate 
and erosions or ulcerations of the oral and/or nasal mucosa 
are not unusual17 (Fig. 2).
The generalized acute form is usually coincident with sys-
temic flares of the disease. Lesions may appear after sun 
exposure, predominate on ultraviolet (UV)-exposed areas 
but progress to widespread symmetric erythematous macu-
lar and papular lesions affecting symmetrically the lateral 
aspect of the arms, elbows, shoulders, knees, and trunk, re-
sembling a maculopapular drug eruption.14 They are often 
associated with diffuse hair thinning, oral and nasal mu-
cosal ulcers, which may progress to nasal septum perfora-
tion.18,19 
Histopathology, that is seldom necessary to confirm the 
diagnosis, shows a very mild interface dermatitis with a der-
mal infiltration with predominance of neutrophils and cario-
clasia, and direct immunofluorescence reveals C3 and IgG 
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granular deposits at the dermal-epidermal junction on le-
sional and often also on normal skin.14,20 A positive ANA is 
found in 95% of ACLE patients, as well as a high incidence of 
anti-double-stranded DNA (anti-dsDNA) and anti-Sm anti-
bodies21 and systemic involvement, particularly lupus nephri-
tis is particularly frequent in these patients. (REF) 
3.2. Subacute Cutaneous Lupus Erythematosus 
SCLE occurs primarily in young to middle-aged women, 
although children and elderly individuals are also affected.15,18
Photosensitivity and anti-SSA/Ro autoantibodies occur in 
70% - 90% of the patients with subacute CLE14,22 and one-
-third to one-half of patients fulfill 4 or more of the classifi-
cation criteria for SLE18 but most commonly they have only 
mild involvement, limited to arthritis and myalgia. A mino-
rity can, nevertheless, develop severe systemic organ invol-
vement with lupus vasculitis, nephritis and central nervous 
system attainment occurring in <10%.25,23 Since anti-SSA/Ro 
autoantibodies are associated with Sjögren syndrome as well 
as SCLE, it is not surprising that an overlap between these en-
tities has been described.
SCLE lesions involve the face in a symmetric distribution 
(sparing the midfacial skin and scalp), the V-area of the neck, 
upper trunk, shoulders and extensor aspects of the upper arms 
but do not extend below the waist18,26 (Fig. 3a,b).
There are two morphologic variants of SCLE: annular and 
papulosquamous. A study of 58 SCLE patients found that 
42% had annular SCLE and 39% exhibited papulosquamous 
SCLE, whereas mixed forms account for 16% of cases.26 Other 
studies however have found that papulosquamous SCLE is 
more common.27,28
Annular lesions are characterized by erythematous scaly 
plaques with raised borders and central clearing, sometimes 
coalescing to produce a polycyclic array.18 The papulosqua-
mous variant presents with chronic psoriasiform or ecze-
matous appearance29 (Fig. 4a,b). Lesions often progress to 
hypopigmentation but with no scarring or atrophy.30 
Histopathology is characterized by a pauci-inflammatory, 
vacuolar, lymphocytic interface dermatitis with hydropic dege-
neration of the basal keratinocytes, occasional apoptotic ke-
ratinocytes, dermal edema and superficial mucin deposition16 
(Fig. 4a,b). DIF immunoglobulin deposits at the dermoepider-
mal junction occur in approximately 60% of cases.31 
3.3. Discoid Lupus Erythematosus
Discoid LE is the most common form of chronic CLE ob-
served among dermatologists. It tends to occur in the fourth 
and fifth decades, and usually is not associated systemic in-
volvement.18 Only about 5% – 10% of patients develop SLE 
throughout their disease course,32,33 the majority at the time of 
diagnosis or within five years, and in these cases they have the 
same autoantibodies found in SLE. 
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Figure 1 - Acute CLE in a patient with anti-ds-DNA and anti-Sm antibodies and severe kidney and central neural system manifestations. (A) Typical 
“butterfly rash”, with erythema involving the malar area and nose and sparing the periorbital area and nasolabial folds, and (B) erythemato-violaceous 
and purpuric lesions on the palms and fingers, especially in the proximal nail folds, simulating dermatomyosisitis.
A B
Figure 2 - Oral erosions in the hard palate in a patient with LES.
204
Educação Médica Contínua
In 80% of cases lesions are localized on the head and 
neck, particularly the upper lip, ears and scalp. A more wi-
despread distribution can occur - generalized discoid LE 
– with a higher propensity to be associated with systemic di-
sease when lesions extend to the trunk,34 palms and soles10 
or the oral mucosa, where they can have a whitish lichenoid 
appearance at the jugal area.35 
Discoid LE usually begins as erythematous scaly papules, 
with well-demarcated borders, that gradually progress to in-
durated coin-shaped plaques, with follicular hyperkeratosis, 
adherent scale, hypopigmentation in the central area and 
hyperpigmentation at the periphery, and later develop scar-
ring with persistent atrophy and alopecia (Fig.s 6 and 7).In 
rare cases, chronic verrucous and hypertrophic lesions may 
also develop.10 
Histology of longstanding active DLE lesions reveals a 
lichenoid reaction pattern, and an intensely inflammatory 
superficial and deep dermal infiltrate with a significant pe-
ri-adnexal infiltrate predominantly of lymphocytes. A sig-
nificant thickening of the basement membrane is frequent 
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Figure 3 - Patient with Subacute CLE in a patient with anti-Ro/SSA antibodies and photosensitivity, arthritis and leukopenia, but no other systemic 
involvement. (A) Facial lesions show with a well-demarcated malar rash sparing the nasolabial folds and eyelids, and erosions on the submucosa of the 
lips and dorsum on the hands. (B) Annular lesions in the V-of the chest, upper arms and abdomen are limited to photoexposed areas.
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in long lasting lesions. Other epidermal changes include 
hyperkeratosis and keratotic follicular plugging. DLE patients 
have a lower incidence of ANA, dsDNA, Sm, and Ro/SSA 
antibodies, as compared to other CLE sub-types.36
3.4. Lupus Panniculitis 
Lupus panniculitis is a rare form of CLE characterized by 
intense inflammation in the adipose tissue which presents as 
painful firm subcutaneous nodules or plaques on the upper 
arms, upper trunk, breasts, buttocks, thighs, face and scalp, 
sometimes with ulceration, and with a high propensity for 
disfiguring, depressed areas with prominent scarring. (Fig 8) 
It tends to have a chronic course, with recurrent flares, and it 
can present as a purely cutaneous disease, while association 
with SLE occurs occasionally.16 
On histology the characteristic finding is a lobular panni-
culitis with prominent dense lymphocytic infiltrate, and mucin 
deposition between collagen bundles.37 
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Figure 5 - Histologic aspect of subacute with intense hydropic dege-
neration of basal keratinocytes, occasional apoptosis, thickening of the 
basement membrane and superficial dermal infiltrate of lymphocytes and 
monocytes (HE, x40).
Figure 6 - Discoid CLE in the face of patients with no systemic symptoms, showing erythematous lesions with thick scales, peripheral hyperpigmen-
tation and older lesions with an atrophic white center with hypopigmentation and hair loss in the beard area. 
Figure 7 - Cicatricial alopecia in chronic CLE in the face of patients with no systemic symptoms, showing erythematous lesions with thick scales (A), 
in a more advanced case with residual hypopigmentation and atrophy with no signs of hair follicles and peripheral hyperpigmentation with some active 




3.5. Chilblain Lupus 
Chilblain lupus is another form of chronic CLE resembling 
frostbite. It consists of pruritic, painful red to violaceous pa-
pules and plaques occurring in cold-exposed areas, such as 
the toes, fingers, and sometimes the nose, elbows, knees and 
lower legs.36 Lesions may progress to central erosions or ulce-
rations and around 20% will develop systemic manifestations.38
A familial form of chilblain lupus with a childhood onset 
is caused by heterozygous mutations in TREX1 or SAMHD1.39 
Affected individuals may have arthralgia and a positive ANA, 
but otherwise do not develop systemic disease. 
3.6 Lupus Erythematosus Tumidus 
Lupus erythematosus tumidus (or intermittent cutaneous 
LE) has distint clinical and histological features, with an extre-
me photosensitivity and a high response to antimalarials,40,41 
and rare association with SLE.40,42
LE tumidus occurs preferentially in men and has a benign 
course, with numerous flares but no progression to scarring 
or atrophy.42 Lesions are located on sun-exposed areas, most 
commonly the face, or upper back, neck, arms and shoul-
ders40 and consist of swollen erythematous papules and 
plaques, without scale or follicular plugging, often forming 
polycyclic plaques with sharp raised borders and smooth sur-
faces, with central clearing (Fig 9). 
3.7 Bullous Lesions in LE 
Bullous lesions occur mostly in SLE can occur either as a 
result of major basal cell vacuolization or massive keratinocyte 
apoptosis (acute syndrome of pan-epidermolysis)43,44 and may 
have an higher association with lupus nephritis and hemato-
logical abnormalities.45,46 
Lesions may simulate erythema multiforme with target-li-
ke lesions (Rowell syndrome)29 but rarely, a dramatic, acute 
extensive eruption like toxic epidermal necrolysis (TEN) may 
appear de novo or occur in patients with a preexisting diag-
nosis (Fig. 10a,b).45 
Other bullous eruptions in SLE can resemble auto-immune 
bullous skin diseases, namely dermatitis herpetiformis (vesi-
cles and bullae in an arciform or figurate distribution on cli-
nically normal-appearing skin or over an erythematous base 
that respond to dapsone), bullous pemphigoid or epidermoly-
sis bullosa acquisita, or they may represent overlap between 
these auto-immune diseases.
3.7 Neonatal Lupus Erythematosus (NLE) 
A neonatal form of SCLE may occur in infants whose mo-
thers transfer anti-SSA/Ro autoantibodies causing cutaneous 
manifestations as well as systemic disease, such as congenital 
heart block, although only about 10% of the children have 
both manifestations.5 
Lesions are clinically and histologically identical to adult 
SCLE. Erythematosus, non-scarring annular plaques frequen-
tly affected the face, especially in the scalp and peri-orbital 
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Figure 8 - Inflammation and facial atrophy due to CLE profundus or 
lupus panniculitis in a patient with minor systemic involvement. 
Figure 9 - A case of LE tumidus with no systemic symptoms, which responded very quickly to antimalarials.
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region ("raccoon or owl eye").2 Photosensitivity is very common 
in NLE, but sun exposure is not required, as occasionally le-
sions are present at birth. Lesions occur shortly after birth (0-2 
months) and as the titers of maternal antibodies degrade wi-
thin the first 6 months2 lesions resolve spontaneously without 
scarring, although dyspigmentation may persist for many 
months, and some children have residual telangiectasias. 
3.8 Nonspecific Cutaneous Lesions in LE
Nonspecific cutaneous lesions in LE are mostly due to vas-
culitis/vasculopathy. They are frequent in SLE patients, particu-
larly during flares.47 
About 10% – 20% of SLE patients have some form of cuta-
neous vasculitis, either small vessel leukocytoclastic vasculitis, 
manifesting as palpable purpura or less frequently as urti-
carial vasculitis with hypocomplementemia (non-pruritic and 
painful long-lasting urticarial lesions that resolve after tran-
sient purpura).14 
Splinter hemorrhages, purpura, urticarial papules, ulcera-
tions or cutaneous infarctions resembling Degos disease or 
atrophie blanche due to vasculitis scars may occur, as well as 
thrombophlebitis and erythromelalgia. Nail fold telangiecta-
sia with prominent tortuous capillaries and hemorrhage can 
be observed on capillaroscopy but abnormalities are more 
subtle than in DM and there are no avascular areas as in 
SSc.48 
Thrombotic vasculopathy, often in the context of antiphos-
pholipd syndrome encompasses a wide range of cutaneous 
manifestations, including livedo reticularis, livedo racemosa, 
Raynaud’s phenomenon and palmar erythema. 
Non-scarring alopecia occurs in 40% – 70% of SLE pa-
tients, with diffuse hair thinning and hair fragility due to telo-
gen/anagen effluvium and lupus hairs (diffuse thinning or a 
receding frontal hairline with broken hairs). In the absence of 
other causes, alopecia is one of the SLICC 2012 criteria for 
the classification of SLE.49 
Other less-frequent non-specific lesions observed particu-
larly in SLE include: - papulonodular mucinosis, presenting as 
skin-colored or slightly erythematous papules and nodules wi-
thout epidermal changes especially involving the trunk, scalp 
and upper extremities; - a Sweet syndrome-like, also named 
non-bullous neutrophilic LE, and other dermatoses with stri-
king cutaneous infiltration of neutrophils related to the acti-
vation of the innate immune response,72 such as amicrobial 
pustulosis of the skin folds, neutrophilic urticarial dermatosis 
and pyoderma gangrenosum.51,52
4. DIAGNOSTIC APPROACH
To properly establish the diagnosis of CLE, systemic in-
volvement of the disease must be excluded first. Also, the 
cutaneous sub-type must be correctly classified. A specific 
diagnostic approach should be based on the findings of pa-
tient history, clinical examination, laboratory studies as well as 
histology. 
Laboratory studies should always include a complete 
blood count (CBC) to evaluate anemia, thrombocytopenia 
or leucopenia, screening for renal involvement with serum 
creatinine and urinalysis. Autoantibody testing is critical and 
should begin with an ANA screen, knowing that a negative 
ANA is helpful, as it is seldom negative in SLE but, on the 
other hand, a positive ANA can be seen in patients with CLE, 
with or without systemic manifestations, and a positive ANA 
is seen in up to 35% of the general population healthy in-
dividuals at a dilution of 1:40, especially in older people.53 
Further autoantibody tests revealing positive dsDNA, Sm and 
ribosomal P is highly specific for SLE, and these autoantibo-
dies serve as markers for the development of systemic di-
sease (54). Other autoantibodies occurring in SLE (although 
not specifically) include antibodies to Ro, La, U1RNP, histones 
and single-stranded DNA (ssDNA). Except anti-Ro/SSA- and 
anti-La/SSB-antibodies, which occur particularly in patients 
with SCLE, there are no other specific autoantibodies to 
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Figure 10 - “TEN-like” lupus erythematosus after sun exposure as a presenting sign in a patient who developed severe SLE. Vesicular and bullous 




differentiate the subtypes of CLE used in routine practice. One 
further possible target of auto-antibodies is annexin 1, which 
has been suggested to play an important role in the preven-
tion of autoimmune diseases.55 A study revealed that, com-
pared to controls, a significantly higher level of anti-annexin 
1 antibodies was observed in CLE patients.56 A high C-RP or 
ESR as well as a low C3 and C4 may indicate severity of sys-
temic involvement. 
Lesional biopsy histology is often critical for the diagnosis, 
and histologic findings depend in large part on the subtype. 
DIF of lesional biopsies can supplement non-definitive histo-
logic findings, detecting immunoglobulins and complement 
deposits at the dermal-epidermal junction. Deposits are ty-
pically granular in appearance, and most commonly contain 
IgG and IgM, and in rare cases, IgA, as well as the com-
plement component C3.57 Non-lesional lupus band tests are 
seen in SLE and have been reported in multiple other auto-
-immune conditions including rheumatoid arthritis, Sjogren’s 
syndrome, dermatomyositis, scleroderma and leprosy.1 
On another level, photoprovocation is a potential adjunct 
to histopathological diagnosis of the CLE sub-type. Photopro-
vocation according to a standardized protocol has been es-
tablished to confirm the diagnosis of CLE and to evaluate the 
photosensitivity of the disease.58 
The present classification criteria for SLE, both ACR (Ame-
rican College of Rheumatology), SLICC and EULAR (European 
League Against Rheumatism) consider cutaneous lesions. 
The more recent EULAR classification, shown to have a high 
sensitivity and specificity, includes positive ANA at least once 
as obligatory entry criterion.59 Other additive criteria grou-
ped in seven clinical domains (constitutional, hematologic, 
neuropsychiatric, mucocutaneous, serosal, musculoskeletal, 
renal) and 3 immunologic domains (antiphospholipid antibo-
dies, complement proteins, SLE-specific antibodies) that are 
weighted individually from 2 to 10. Patients that score ≥10 
points are classified as SLE. 
5. TREATMENT OF CUTANEOUS LE
When managing CLE, preventing the formation of new 
lesions and improving skin appearance are important goals, 
achieved through a combination of patient education (trigger 
avoidance) and topical and systemic therapies. 
Sun protection is a crucial part of the management becau-
se UV irradiation exacerbates both skin and also for systemic 
disease in SLE patients. Both UVA and UVB irradiation have 
been shown to induce CLE lesions.60 Sun protection should 
be emphasized even in patients whose skin lesions are not 
induced or exacerbated by sun exposure and also to prevent 
skin cancer particularly in hypopigmented skin or in chronic 
discoid lesions and in those on immunosuppressive therapy. 
Based on a vehicle-controlled, randomized, double-blind 
trial of 25 photosensitive CLE patients, which reported 100% 
protection from UVA and UVB irradiation with a broad-spec-
trum sunscreen,61 sunscreen with a sun protection factor (SPF) 
of at least 50 should be applied to exposed skin 20-30 min 
prior to expected exposure on a daily basis, and more often if 
sun sensitivity is high or sun exposure is intense or prolonged. 
Protective clothing is also very important (often, the proper 
protective clothing is significantly better than sunscreens) and 
sun avoidance is even more effective. 
Smoking cessation should be strongly encouraged62,63 as 
it enhances toll-like receptor 9 responsiveness and IFN type 
1 production in plasmacytoid dendritic cells.64 A larger per-
centage of cigarette smokers are represented amongst CLE 
patients and smokers may have more extensive cutaneous 
disease and tend to be more refractory to systemic therapies. 
Cutaneous lesions in SLE usually benefit from systemic 
treatments and can improve in parallel with the control of 
systemic disease, but sometimes the skin may oblige speci-
fic additional cutaneous and systemic therapies. Treatment of 
CLE should begin with topicals, but topical therapy is often 
insufficient in SCLE and LE tumidous.65
5.1 Topical Therapy 
Topical (or intralesional) corticosteroids are a mainstay 
of topical therapy, as they are rapid to produce therapeutic 
effects. Although systemic side effects of corticosteroids are 
largely avoided, cutaneous side effects (atrophy, telangiec-
tasia) are not, as there is a need to use potent topical corti-
costeroids often as ointments. For safety reasons, the lowest 
potency allowing for resolution should be used for the shor-
test duration possible and only on affected sites 
In active discoid lesions and LE tumidus, and particularly 
in refractory localized lesions, monthly injections of intralesio-
nal triamcinolone (4-5 mg/mL) can be very effective.66  
Because of the concern with cutaneous side effects of cor-
ticosteroids, topical calcineurin inhibitors have emerged as 
an alternative for various CLE sub-types,67 especially for chil-
dren and facial lesions A double-blind, randomized control 
trial treated half the face of 20 patients with tacrolimus 0.1% 
ointment and the other half with clobetasol propionate 0.05% 
ointment showed equal efficacy; nevertheless, 61% of pa-
tients developed telangiectasia on the clobetasol side as early 
as week 3, indicating that tacrolimus may be a safer option.68 
Most ACLE and CCLE lesions respond well to treatment, 
Physical treatments available for CLE include laser the-
rapy, cryotherapy and dermabrasion. Efficacy of pulsed-dye 
and argon lasers has been shown in several case reports and 
series. An open prospective study of 12 discoid LE patients 
treated with pulsed-dye laser demonstrated efficacy after 6 
weeks of treatment, but purpura, pain and post-inflammatory 
pigmentation were the reported as side effects.69 
5.2. Systemic Therapy 
Systemic therapies are added to topical therapy in situa-
tions refractory to topical treatments, or in cases where there 
is widespread involvement or significant tendency to scarring. 
With the exception of thalidomide, drugs used for the treat-
ment of the various CLE sub-types are generally also used for 
SLE treatment.
Antimalarial therapy, with response rates up to 95%, is 
considered the first-line systemic therapy for all CLE sub-types 
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and it remains the gold standard for systemic therapy. Ne-
vertheless, response to antimalarials is relatively slow: 2 or 3 
months for results to be apparent, and several more months 
to achieve maximal efficacy.
Hydroxychloroquine sulfate is considered the drug of 
choice, at 200-400 mg/day or up to 6.5 mg/kg ideal body 
weight/day. It is considered safer than its more effective coun-
terpart, chloroquine, due to a lower incidence of retinopathy. 
In patients unresponsive to hydroxychloroquine, quinacrine 
100 mg may be added for a synergistic effect, without an in-
creased risk of retinopathy.70 This combined therapy heightens 
efficacy, with a reported 67% improvement rate in patients 
who had previously failed hydroxychloroquine monothera-
py.70 If a patient fails the hydroxychloroquine plus quinacri-
ne combination, a switch to chloroquine may be considered, 
but due to the unacceptable risk of retinopathy, hydroxychlo-
roquine and chloroquine should not be used together.71 For 
chloroquine, the eye toxicity-minimizing dose is < 3.5-4 mg/
kg ideal body weight/day. Antimalarials are usually is well 
tolerated but besides ocular toxicity, xerosis, lichenoid drug 
eruptions, blue–gray skin hyperpigmentation, gastrointestinal 
upset, myopathy and cardiomyopathy may occur. Quinacrine 
in particular can cause yellow discolouration of skin, scle-
ra and bodily fluids. Regular retinopathy screenings are re-
commended by the American Academy of Ophthalmology, 
at intervals based on the risk status.72 Antimalarial therapy 
is contraindicated in patients with pre-existing retinopathy, 
blood disorders and myasthenia gravis.73 
Cutaneous disease refractory to antimalarials is often re-
fractory to other systemic treatments, but risks are deemed to 
be worth the potential benefits for oral retinoids, thalidomide 
or lenalidomide, systemic corticosteroids, immunosuppres-
sive agents such as mycophenolate mofetil or methotrexate, 
or biological agents.  Nevertheless, 10% of patients are in-
tolerant or have recalcitrant lesions and there are no large 
studies addressing the efficacy of current therapies for re-
fractory CLE.
Systemic corticosteroids are usually avoided, taking into 
consideration the well-known deleterious effects of prolonged 
therapy, particularly in LE patients who are at an increased 
risk of developing avascular necrosis. Corticosteroids can oc-
casionally be considered as a short course option in patients 
with severe disease as a brigde therapy before the onset of 
action of other therapies. Appropriate doses of prednisone 
(0.5-1.0 mg/kg/day) can be tapered over 2-4 weeks.74 In 
cases with moderate to severe organ involvement, corticos-
teroids are the primary treatment, possibly with pulse cyclo-
phosphamide and/or pulse corticosteroids.
Methotrexate (7.5-25 mg orally or subcutaneously once 
a week) is advised in antimalarial-refractory cases as a se-
cond line therapy, especially in ACLE and CCLE, and also as 
a corticosteroid-sparing agent.74 A retrospective analysis of 
43 treatment-refractory CLE patients found improvement in 
98% of cases.75 
Oral retinoids have been especially useful in hypertro-
phic CLE and discoid lupus.76 Multiple case reports attest 
isotretinoin’s efficacy66 and in a randomized controlled trial, 
acitretin was demonstrated to be effective in half of CLE pa-
tients. Recommended dosages of acitretin and isotretinoin 
are 0.2-1.0 mg/kg/day. Since retinoids are highly teratoge-
nic, it is critical to ensure effective contraception in women 
of childbearing potential, both during and after treatment.73 
Dapsone has been used effectively in bullous LE, lupus 
panniculitis, oral ulceration, as well as vasculitic and urtica-
rial lesions. Hyperkeratotic lesions do not respond to dapso-
ne,77 but the bullous form responds very well.78 Combined 
results of three case series of 55 CLE patients treated with 
dapsone demonstrated a 55% improvement rate.66 Dapsone 
is started at 50 mg daily, with 25 mg week increments, until 
a maximum of 200 mg/day. Regular monitoring for haema-
tologic and hepatic toxicities is crucial. Dapsone is contra-in-
dicated in patients with glucose-6-phosphate dehydrogenase 
deficiency. 
Mycophenolate mofetil (MMF) has been shown to be 
effective in all CLE sub-types in small studies and multiple 
case reports. In an open pilot trial with patients with SLE trea-
ted with MMF, improvements in skin manifestations were no-
ticed.79 MMF is usually dosed at 1.0 to 3.0 g/day and needs 
renal dosage adjustment. Adverse effects that are commonly 
seen with MMF include leukopenia, vomiting and abdominal 
cramping.
Azathioprine, was also shown to successfully treat DLE in 
several small case series.80-82
Multiple case series validate the use of thalidomide in 
CCLE, SCLE and LE tumidus.83,84 The initial recommended 
dose (400 mg/day) can be tapered down to 50-100 mg/day. 
Lenalidomide (5-10 mg/day) is a thalidomide analogue more 
recently used in a case series of refractory CLE and two small 
open-label trials.85-87 Both drugs are very and rapidly effective 
in severe-treatment resistant cases,88 and both are used in 
severe CLE, especially in deep-seated and discoid lesions.89 
They are mostly used as remission-inducing agents in combi-
nation with antimalarials. Thalidomide is a potent teratogen, 
and a frequent side effect is peripheral neuropathy (25% - 
30%), which can be irreversible and whose frequency is maxi-
mal during the first year of treatment.90,91 Lenalidomide may 
have a lower risk of developing peripheral neuropathy. Addi-
tional potential side effects are drowsiness, amenorrhea, and 
thrombotic events. 
Intravenous immunoglobulin (IVIG) has proven effective 
as a remission-inducing agent, especially for SCLE, but po-
sitive results are generally short lived. It should be reserved 
to gain rapid control of severe disease, while initiating other 
long-term therapies. 
Rituximab is a chimeric monoclonal antibody specific for 
human CD20, with a poor efficacy in DLE and variable effica-
cy for SCLE, implying that the underlying pathogenesis is not 
mainly dependent on B cells.92 
Belimumab is another monoclonal antibody used in SLE 
that reduces B cell survival, but efficacy in CLE has not been 
well studied. Nevertheless, in a case series of five patients with 
ACLE, SCLE, and/or DLE, with the addition of intravenous 
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belimumab all had significant improvement in disease acti-
vity evaluated by the CLASI (Cutaneous Lupus Erythematosus 
Disease Area and Severity Index).93 
Additional therapies that have been used in the treatment 
of CLE include ustekinumab, phenytoin, sulfasalazine, dana-
zol and extracorporeal photophoresis. Agents currently under 
investigation for their efficacy and safety in CLE include topi-
cal R-salbutamol oral apremilast and intravenous sirukumab 
(a human anti-IL-6 monoclonal antibody). Additional infor-
mation is necessary to establish their efficacy and safety, al-
though early findings suggest that these agents may constitute 
valid treatment alternatives. 
CONCLUSION
LE can present with an extremely broad spectrum of cuta-
neous manifestations, and cutaneous lesions occur in 80% of 
patients with SLE and often as the initial manifestation of the 
disease; thus, their early recognition is of major importance, 
in order to provide an adequate management of affected 
patients. 
Due to their different prognosis, the diagnosis of CLE re-
quires further classification into the different sub-types, which 
is accomplished by evaluating clinical and histologic findings. 
Appropriate laboratory studies should be individually reques-
ted in order to exclude extra-cutaneous involvement. 
Further research will identify and refine the physiopatho-
logical mechanisms that lead to the disease, and facilitate 
development of specific therapies, which go beyond general 
immunosuppressive approaches, especially for recalcitrant 
disease. 
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Educação Médica Contínua
1.  Regarding CLE treatment, choose the right 
sentence:
a) Talidomide frequently causes peripheral neuropa-
thy, which is always reversible with its discontinua-
tion.
b) In refractory cases, hydroxychloroquine and chlo-
roquine can be used together, without significant 
risk of retinopathy.
c) Hyperkeratotic lesions respond very well to dap-
sone.
d) Bullous lesions respond very well to dapsone.
2. Choose the false sentence:
a) LE tumidus, initially included within the chronic 
subtype, is considered a separate form of cuta-
neous LE. 
b) The LE-nonspecific manifestations are more fre-
quently seen in patients with systemic disease.
c) The great majority of patients with discoid LE 
eventually develop SLE throughout their disease 
course.
d) The more recent EULAR classification for includes 
positive ANA at least once as obligatory entry cri-
terion. 
3. Choose the right sentence: 
a) In neonatal lupus, lesions are clinically and his-
tologically identical to adult ACLE, and systemic 
disease may occur.
b) Concerning lupus panniculitis, on histology, the 
characteristic finding is a septal panniculitis with 
prominent dense lymphocytic infiltrate.
c) ACLE lesions tend to be sun-induced and usually 
resolve with proeminent scarring.
d) Lupus erythematosus tumidus lesions characteris-
tically have extreme photosensitivity. 
VErifiquE o quE aprENdEu
Correct answers: 1-d); 2-c); 3-d).
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